Acurx Pharmaceuticals (ACXP) Insider Trading & Ownership $0.87 +0.01 (+0.86%) (As of 10:33 AM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Acurx Pharmaceuticals (NASDAQ:ACXP) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage29.60%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$75,000.60Number OfInsiders Selling(Last 3 Years)0 Get ACXP Insider Trade Alerts Want to know when executives and insiders are buying or selling Acurx Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ACXP Insider Buying and Selling by Quarter Ad Diversified Trading InstituteGenesis leading the smart algo revolution?I’m revealing an exciting breakthrough that can help trade the markets unlike anything you’ve ever seen before… Because with my BRAND NEW smart algo you’ll always have a constant stream of alerts firing off in your back pocket to choose from. Here’s why: It does all the heavy lifting for you… automatically. Stock Ticker, Entry Price, Profit Target, Stop Loss, and even an Individual Chart!You’ll want to see what I’ve put on this page right here Acurx Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/27/2022Carl SailerDirectorBuy19,737$3.80$75,000.60 (Data available from 1/1/2013 forward) ACXP Insider Trading Activity - Frequently Asked Questions Who is on Acurx Pharmaceuticals's Insider Roster? The list of insiders at Acurx Pharmaceuticals includes Carl Sailer. Learn more on insiders at ACXP. What percentage of Acurx Pharmaceuticals stock is owned by insiders? 29.60% of Acurx Pharmaceuticals stock is owned by insiders. Learn more on ACXP's insider holdings. Acurx Pharmaceuticals Key ExecutivesMr. Robert J. DeLuccia (Age 78)Co-Founder & Executive Chairman Compensation: $701.54kMr. David P. Luci CPA (Age 57)Esq., J.D., Co-Founder, President, CEO, Corporate Secretary & Director Compensation: $668.98kMr. Robert G. Shawah CPA (Age 57)CPA, Co-Founder & CFO Compensation: $470.29k More Insider Trading Tools from MarketBeat Related Companies Janone Insider Trades Immuneering Insider Trades Shattuck Labs Insider Trades Iterum Therapeutics Insider Trades AlloVir Insider Trades IO Biotech Insider Trades Celularity Insider Trades Omega Therapeutics Insider Trades vTv Therapeutics Insider Trades Aileron Therapeutics Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:ACXP) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
